NCT01011101

Brief Summary

Background:

  • Researchers are studying how humans are able to move our eyes to a remembered region even when the target has disappeared. The ability to do this suggests that the brain can keep track of where the eyes have looked, without an external target for continued reference. This is called corollary discharge.
  • Other research has indicated that patients with schizophrenia might have difficulty monitoring their eye movements. The corollary discharge process may be defective in patients with schizophrenia, and perhaps delayed in time. Researchers have developed a test to examine this possibility in the hope of learning more about schizophrenia and eye movement. Objectives: \- To assess whether there is a defect in internal monitoring of eye movements in patients with schizophrenia. Eligibility:
  • Individuals over 18 years of age who are able to give informed consent and are able to concentrate on a 20-minute task that involves following projected targets and moving their eyes to remembered locations.
  • Individuals with schizophrenia will be recruited from an ongoing NIH protocol studying schizophrenia.
  • In addition healthy will be recruited for this protocol. Design:
  • Researchers will check participants' vision in each eye, and ask them to sit at a machine that measures eye movement in order to complete research tasks. Researchers will monitor participants ability to complete these tasks.
  • The first task involves simply following a target that jumps to different parts of the screen.
  • The second is a 2-step task, in which a participant is asked to look at two separate light targets and then look at the remembered target positions when the lights are off.
  • This protocol does not provide treatment. Participants will remain under the care of their own physicians during participation in this protocol.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 2, 2009

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

November 10, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 11, 2009

Completed
6.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2016

Completed
Last Updated

October 6, 2017

Status Verified

August 16, 2016

First QC Date

November 10, 2009

Last Update Submit

October 5, 2017

Conditions

Keywords

Saccadic Eye MovementsSchizophreniaHealthy VolunteerHV

Outcome Measures

Primary Outcomes (1)

  • Comparison of recordings between groups

    End of study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult subjects over 18 years of age who are able to give informed consent and are able to concentrate on a task for 20 minutes which involves following projected targets and moving their eyes to remembered locations.

You may not qualify if:

  • Large refractive error requiring strong glasses. Glasses may interfere with the video eye movement recording system. However, participants may wear contact lenses. Subjects with a history of eye disease affecting vision or eye movements will also be excluded.
  • Participants with guardians will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry. 1999 Oct 1;46(7):908-20. doi: 10.1016/s0006-3223(99)00152-3.

    PMID: 10509174BACKGROUND
  • Campanella S, Guerit JM. How clinical neurophysiology may contribute to the understanding of a psychiatric disease such as schizophrenia. Neurophysiol Clin. 2009 Feb;39(1):31-9. doi: 10.1016/j.neucli.2008.12.002. Epub 2009 Jan 9.

    PMID: 19268845BACKGROUND
  • Duhamel JR, Goldberg ME, Fitzgibbon EJ, Sirigu A, Grafman J. Saccadic dysmetria in a patient with a right frontoparietal lesion. The importance of corollary discharge for accurate spatial behaviour. Brain. 1992 Oct;115 ( Pt 5):1387-402. doi: 10.1093/brain/115.5.1387.

    PMID: 1422794BACKGROUND

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Edmond J FitzGibbon, M.D.

    National Eye Institute (NEI)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2009

First Posted

November 11, 2009

Study Start

November 2, 2009

Study Completion

August 16, 2016

Last Updated

October 6, 2017

Record last verified: 2016-08-16

Locations